Quick Takeaways
- Sands Capital Life Sciences Pulse Fund II, L.P. filed SCHEDULE 13G/A for Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (ACRV).
- Disclosed ownership: 6.8%.
- Date of event: 30 Jun 2025.
Sands Capital Life Sciences Pulse Fund II, L.P. - 30 Jun 2025 SCHEDULE 13G/A Report for Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (ACRV)
- Filing Manager
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Reporting Manager
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Symbol
- ACRV
- Shares outstanding
- 31,214,779 shares
- Disclosed Ownership
- 2,122,605 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Aug 2025, 11:12:23 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Sands Capital Life Sciences Pulse Fund II, L.P. disclosed 6.8% ownership in Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (ACRV) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Aug 2025, 11:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | 2,122,605 | 0 | 2,122,605 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P. | |
| Sands Capital Alternatives, LLC | 6.8% | 2,122,605 | 0 | 2,122,605 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel | |
| SANDS FRANK M. | 6.8% | 2,122,605 | 0 | 2,122,605 | /s/ Frank M. Sands | Frank M. Sands |